对抗性高血压的新药:待定问题?
Francesco Fici1, Nicolas Roberto Robles2, Istemihan Tengiz3
1Department of Cardiovascular Risk, Salamanca University, Salamanca, Spain;Milano-Bicocca University, Milan, Italy.
概括
新的抗高血压药物正在开发中,以应对耐药高血压患者持续的心血管风险. 本综述考察了针对失控高血压的新型药物类别.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 药物发现 药物发现 药物发现
背景情况:
- 目前的抗高血压药物可以降低心血管风险,但不能消除它.
- 在接受治疗的高血压患者中,心血管风险仍然存在.
- 需要新的抗高血压药物来治疗耐药高血压.
研究的目的:
- 审查新兴的抗高血压药物用于治疗耐药高血压.
- 突出高血压管理中的新型治疗点和药物.
主要方法:
- 关于新型抗高血压药物类别的最新研究的文献综述.
- 专注于非类固醇矿物质皮质类受体对抗剂,阿尔多氨酸合成酶抑制剂等.
主要成果:
- 几种新型药物类别在向抗高血压方面表现有前途.
- 这些药物包括矿物质皮质类受体对抗剂,阿尔多氨酸合成酶抑制剂和大脑氨酸- ангиотензин系统阻断剂.
结论:
- 新型药理学方法对于治疗耐药高血压至关重要.
- 这些新药具有进一步降低高血压患者心血管风险的潜力.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
Antihypertensive Drugs: Direct Renin Inhibitors
830
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
830
Hypertension IV: Drug Therapy and Lifestyle Modifications
40
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
40
Antihypertensive Drugs: Angiotensin II Receptor Blockers
928
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
928
Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26


